Dr. Albert Grinshpun, MD, MSc

Multidimensional Molecular Cancer Therapeutics
  • Dr. Albert Grinshpun completed his M.D. at the Hebrew University in Jerusalem, Israel. During his M.D. training he also completed M.Sc. in gene therapy, under the mentorship of Prof. Eithan Galun. He then went on and completed his service in the Israel Defense Forces, followed by a residency in Medical Oncology at the Sharett Institute of Oncology of the Hadassah-Hebrew University Medical Center. During this training program, he also completed a research fellowship at the Weizmann Institute where he investigated tumor microbiome (Straussman lab). During his residency, mentored by Prof. Tamar Peretz, Prof. Yuval Dor and Prof. Beatrice Uziely he was highly successful in receiving several core foundation funding including the Ministry of Science Personalized Medicine grant, Physician-Scientist award from the Israel Science Foundation (ISF) to study cell free DNA in colorectal cancer and the Conquer Cancer (ASCO)-Israel Cancer Research Fund for a project focused on breast cancer detection using liquid biopsy. He has published more than 30 peer reviewed original articles. Among these publications are manuscripts published in Annals of Oncology and JAMA Oncology which he first authored or first co-authored.
  • In 2021, Dr. Grinshpun joined the international Goldfarb Advanced Fellowship program in breast oncology at Dana-Farber/Harvard Cancer Center in Boston. Currently, he is working under the mentorship of Rinath Jeselsohn MD PhD, renowned specialist in Estrogen receptor biology, focusing on mechanism of endocrine resistance in metastatic hormone receptor-positive breast cancer and ctDNA studies. Additionally, Albert is involved in translational research, clinical trial design and multidisciplinary patient care.
  • Albert is expected to return to Hadassah in September 2023 to continue his clinical work and lead scientific progress in the Multidimensional Molecular Cancer Therapeutics Lab.
Recent Key Publications

1. A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer.

Grinshpun A, Kustanovich A, Neiman D, Lehmann-Werman R, Zick A, Meir K, Vainer E, Granit RZ, Arad A, Daskal N, Schwartz R, Sapir E, Maoz M, Tahover E, Moss J, Ben-Dov IZ, Peretz T, Hubert A, Shemer R, Dor Y.

Int J Cancer. 2023 Apr 1;152(7):1444-1451.

 

2. ESR1 activating mutations: From structure to clinical application.

Grinshpun A, Chen V, Sandusky ZM, Fanning SW, Jeselsohn R.

Biochim Biophys Acta Rev Cancer. 2022 Nov 4;1878(1):188830. Review.

 

3. Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Hormone Receptor-Positive Breast Cancer.

Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Getz G, Jeselsohn R.

Clin Cancer Res. 2022 Oct 10:CCR-22-2305.

 

4. Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Rottenberg Y*, Grinshpun A*, Ben-Dov IZ, Oiknine Djian E, Wolf DG, Kadouri L.  

JAMA Oncol. 2021 Nov 23:e216764. Research letter.

* Equal contribution

 

5. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment

Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L.

ESMO Open. 2021 Dec;6(6):100283. doi: 10.1016/j.esmoop.2021.100283.

 

6. High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis

Shraga S*, Grinshpun A*, Zick A, Kadouri L, Cohen Y, Maimon O, Adler-Levy Y, Zeltzer G, Granit A, Maly B, Carmon E, Meiner V, Sella T, Hamburger T, Peretz T.

Front Oncol. 2021 Sep 2;11:683656.

* Equal contribution

 

7. Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2

Jeselsohn R, Schiff R, Grinshpun A.

Cancer Cell. 2021 Oct 11;39(10):1302-1305. Preview

 

8. Circulating Breast-derived DNA Allows Universal Detection and Monitoring of Localized Breast Cancer

Moss J*, Zick A*, Grinshpun A*, Carmon E, MaozM, Ohana BL, Abraham O, Arieli O, Germansky L, Meir K, Glaser B, Shemer R, Uziely B, Dor Y.

Annals of Oncology, 2020 Mar;31(3):395-403

* Equal contribution

 

9. Life and Death of Circulating Cell-Free DNA

Kustanovich A, Shwarz R, Peretz T, Grinshpun A.

Cancer Biology & Therapy. 2019;20(8):1057-1067. Review

Linkedin-in
HCRI
Immuno Oncology
Contact Us
Copyright Hadassah Medical Organization and HCRI © 2024 All rights reserved
Skip to content